Now or never: Optimal antihypertensive therapy in the elderly

Preventive Cardiology

Volumn 11, Issue 4, 2008, Pages 201-209

  Prisant, L Michael ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; AMLODIPINE PLUS VALSARTAN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL FUMARATE PLUS HYDROCHLOROTHIAZIDE; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL PLUS HYDROCHLOROTHIAZIDE; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; INDAPAMIDE; LOSARTAN; PLACEBO; RAMIPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; VERAPAMIL; ANGIOTENSIN RECEPTOR ANTAGONIST;

AEROBIC EXERCISE; ALCOHOL CONSUMPTION; BLOOD PRESSURE REGULATION; BLOOD PRESSURE VARIABILITY; BRADYCARDIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE CONTROL; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; ELDERLY CARE; HEART BLOCK; HEART FAILURE; HEART OUTPUT; HEART RATE; HUMAN; HYPERTENSION; HYPOKALEMIA; INTESTINE ABSORPTION; LIFESTYLE MODIFICATION; LIVER BLOOD FLOW; MONOTHERAPY; MORTALITY; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PREVALENCE; PRIORITY JOURNAL; PULSE PRESSURE; RENOVASCULAR HYPERTENSION; REVIEW; SODIUM RESTRICTION; SPLANCHNIC BLOOD FLOW; STOMACH PH; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; AGE; AGED; AGING; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; FOLLOW UP; GERIATRIC ASSESSMENT; MALE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GERIATRIC ASSESSMENT; HUMANS; HYPERTENSION; MALE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 66949148736     PISSN: 1520037X     EISSN: 17517141     Source Type: Journal    
DOI: 10.1111/j.1751-7141.2008.00005.x     Document Type: Review

References (75)

1. Fields LE, Burt VL, Cutler JA, et al. The burden of adult hypertension in the United States 1999 to 2000: A rising tide. Hypertension. 2004;44:398-404.
2. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49:69-75.
3. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics: 2007 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115:e69-e171.
4. Prisant LM. Clinical trials of hypertension in the older patient. In: Prisant LM, ed. Hypertension in the Elderly. Totowa, NJ: Humana Press; 2005:91-116.
5. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:887-898.
6. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 2001;345:479-486.
7. Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: Current outcomes and control in the community. JAMA. 2005;294:466-472.
8. Ostchega Y, Dillon CF, Hughes JP, et al. Trends in hypertension prevalence, awareness, treatment, and control in older U.S. adults: Data from the National Health and Nutrition Examination Survey 1988 to 2004. J Am Geriatr Soc. 2007;55:1056-1065.
9. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206-1252.
10. Prisant LM, Jackson TW. Clinical evaluation of the elderly hypertensive. In: Prisant LM, ed. Hypertension in the Elderly. Totowa, NJ: Humana Press; 2005:135-144.
11. Franklin SS, Jacobs MJ, Wong ND, et al. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension. 2001;37:869-874.
12. Prisant LM, Gujral JS, Mulloy AL. Hyperthyroidism: A secondary cause of isolated systolic hypertension. J Clin Hypertens (Greenwich). 2006;8:596-599.
13. Prisant LM, Landolfo C, Thornton J, et al. Heart failure in the older hypertensive patient. In: Prisant LM, ed. Hypertension in the Elderly. Totowa, NJ: Humana Press; 2005:197-228.
14. Prisant LM, Mondy JS III. Abdominal aortic aneurysm. J Clin Hypertens (Greenwich). 2004;6:85-89.
15. Sowers JR, Prisant LM. Treatment of hypertension in the elderly patient with diabetes. In: Prisant LM, ed. Hypertension in the Elderly. Totowa, NJ: Humana Press; 2005:451-469.
16. Anderson GH Jr, Blakeman N, Streeten DHP. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens. 1994;12:609-615.
17. Prisant LM, Dillard TA, Blanchard AR. Obstructive sleep apnea syndrome. J Clin Hypertens (Greenwich). 2006;8:746-750.
18. Prisant LM, Harrell DU. Nonpharmacological trials in the older hypertensive patient. In: Prisant LM, ed. Hypertension in the Elderly. Totowa, NJ: Humana Press; 2005:69-90.
19. Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: A randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). JAMA. 1998;279:839-846.
20. Chaudhry SI, Krumholz HM, Foody JM. Systolic hypertension in older persons. JAMA. 2004;292:1074-1080.
21. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 ESH-ESC practice guidelines for the management of arterial hypertension. J Hypertens. 2007;25:1751-1762.
22. Montamat SC, Cusack BJ, Vestal RE. Management of drug therapy in the elderly. N Engl J Med. 1989;321:303-309.
23. Greenblatt DJ, Sellers EM, Shader RI. Drug therapy: Drug disposition in old age. N Engl J Med. 1982;306:1081-1088.
24. Drincic V, Koshy S, Bakris G. Angiotensin receptor blocker use for hypertension treatment in the elderly. Ann Long-Term Care. 1999;7:305-308.
25. Demers C, McMurray JJ, Swedberg K, et al. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. JAMA. 2005;294:1794-1798.
26. Mochizuki S, Dahlöf B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): A randomised, open-label, blinded endpoint morbidity-mortality study. Lancet. 2007;369:1431-1439.
27. Izzo JL Jr, Levy D, Black HR. Clinical advisory statement: Importance of systolic blood pressure in older Americans. Hypertension. 2000;35:1021-1024.
28. Materson BJ, Reda DJ, Cushman WC, for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Department of Veterans Affairs single-drug therapy of hypertension study: Revised figures and new data. Am J Hypertens. 1995;8:189-192.
29. Franse LV, Pahor M, Di Bari M, et al. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension. 2000;35:1025-1030.
30. Ibrahim MM. RAS inhibition in hypertension. J Hum Hypertens. 2006;20:101-108.
31. Mancia G, Seravalle G, Grassi G. Tolerability and treatment compliance with angiotensin II receptor antagonists. Am J Hypertens. 2003;16:1066-1073.
32. Fogari R, Zoppi A. Effect of antihypertensive agents on quality of life in the elderly. Drugs Aging. 2004;21:377-393.
33. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875-886.
34. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA. 1998;279:1903-1907.
35. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: Is it a wise choice? Lancet. 2004;364:1684-1689.
36. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366:1545-1553.
37. Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: A meta-analysis. CMAJ. 2006;174:1737-1742.
38. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2000;283:1967-1975.
39. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359:995-1003.
40. Lindholm LH, Ibsen H, Dahlöf B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359:1004-1010.
41. Prisant LM. Should beta blockers be used in the treatment of hypertension in the elderly? J Clin Hypertens (Greenwich). 2002;4:286-294.
42. Prisant LM, Doll NC. Hypertension: The rediscovery of combination therapy. Geriatrics. 1997;52:28-30.
43. Materson BJ, Reda DJ, Preston RA, et al. Response to a second single antihypertensive agent used as monotherapy for hypertension after failure of the initial drug. Arch Intern Med. 1995;155:1757-1762.
44. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
45. Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003;289:2073-2082.
46. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393-404.
47. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA. 2003;290:2805-2816.
48. Black HR, Elliott WJ, Neaton JD, et al. Baseline characteristics and early blood pressure control in the CONVINCE trial. Hypertension. 2001;37:12-18.
49. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: A meta-analysis. Am J Med. 2007;120:713-719.
50. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet. 2003;361:117-124.
51. Kunz R, Wolbers M, Glass T, et al. The COOPERATE trial: A letter of concern. Lancet. 2008;371(9624):1575-1576.
52. Vantrimpont P, Rouleau JL, Wun CC, et al. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. J Am Coll Cardiol. 1997;29:229-236.
53. Remme WJ, Riegger G, Hildebrandt P, et al. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction: The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN). Cardiovasc Drugs Ther. 2004;18:57-66.
54. Krum H, Carson P, Farsang C, et al. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: Results from Val-HeFT. Eur J Heart Fail. 2004;6:937-945.
55. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559.
56. Conlin PR, Spence JD, Williams B, et al. Angiotensin II antagonists for hypertension: Are there differences in efficacy? Am J Hypertens. 2000;13:418-426.
57. Weir MR, Levy D, Crikelair N, et al. Time to achieve blood-pressure goal: Influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy. Am J Hypertens. 2007;20:807-815.
58. Weir MR, Crikelair N, Levy D, et al. Evaluation of the dose response with valsartan and valsartan/hydrochlorothiazide in patients with essential hypertension. J Clin Hypertens. 2007;9:103-112.
59. Saseen JJ, Carter BL, Brown TE, et al. Comparison of nifedipine alone and with diltiazem or verapamil in hypertension. Hypertension. 1996;28:109-114.
60. Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens. 2007;20:11-20.
61. Poldermans D, Glazer R, Karagiannis S, et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther. 2007;29:279-289.
62. Ridker PM, Danielson E, Rifai N, et al. Valsartan, blood pressure reduction, and C-reactive protein: Primary report of the Val-MARC trial. Hypertension. 2006;48:73-79.
63. Frishman WH, Burris JF, Mroczek WJ, et al. First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. J Clin Pharmacol. 1995;35:182-188.
64. Neutel JM, Smith DH, Weber MA, et al. Efficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: The Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) study. J Clin Hypertens (Greenwich). 2005;7:641-646.
65. Pool JL, Glazer R, Weinberger M, et al. Comparison of valsartan/ hydrochlorothiazide combination therapy at doses up to 320/25mg versus monotherapy: A double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther. 2007;29:61-73.
66. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497.
67. Egan BM, Lackland DT, Cutler NE. Awareness, knowledge, and attitudes of older Americans about high blood pressure. Arch Intern Med. 2003;163:681-687.
68. Duru OK, Vargas RB, Kermah D, et al. Health insurance status and hypertension monitoring and control in the United States. Am J Hypertens. 2007;20:348-353.
69. Fung V, Huang J, Brand R, et al. Hypertension treatment in a Medicare population: Adherence and systolic blood pressure control. Clin Ther. 2007;29:972-984.
70. Borghi C, Veronesi M, Dormi A, et al. Persistence of treatment and blood pressure control in elderly hypertensive patients treated with different classes of antihypertensive drugs. Am J Geriatr Cardiol. 2007;16:280-286.
71. Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health-Syst Pharm. 2007;64:1279-1283.
72. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care. 2001;10(2 suppl):6-10.
73. Kuschnir E, Acuña E, Sevilla D, et al. Treatment of patients with essential hypertension: Amlodipine 5mg/benazepril 20mg compared with amlodipine 5mg, benazepril 20mg, and placebo. Clin Ther. 1996;18:1213-1224.
74. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-1906.
75. Schrader J, Lüders S, Kulschewski A, et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: Principal results of a prospective randomized controlled study (MOSES). Stroke. 2005;36:1218-1226.